nivolumab


( Last Updated : July 20, 2021)
Generic Name:
nivolumab
Project Status:
Pending
Therapeutic Area:
Gastroesophageal junction or esophageal adenocarcinoma
Manufacturer:
Bristol-Myers Squibb
Call for patient/clinician input open:
Brand Name:
Opdivo
Project Line:
Reimbursement Review
Project Number:
PC0259-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.